Put Options

14 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$130.86 - $143.19 $981,450 - $1.07 Million
-7,500 Reduced 89.29%
900 $123,000
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $880,381 - $1.1 Million
8,300 Added 8300.0%
8,400 $1.11 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $9,402 - $11,710
100 New
100 $11,000
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $210,105 - $274,949
-2,900 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $3.29 Million - $3.78 Million
-38,200 Reduced 92.94%
2,900 $278,000
Q3 2020

Nov 13, 2020

SELL
$96.16 - $135.15 $1.58 Million - $2.22 Million
-16,400 Reduced 28.52%
41,100 $3.95 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $1.24 Million - $1.9 Million
-14,600 Reduced 20.25%
57,500 $7.02 Million
Q1 2020

May 14, 2020

BUY
$75.11 - $113.76 $3.45 Million - $5.22 Million
45,900 Added 175.19%
72,100 $6.24 Million
Q4 2019

Feb 13, 2020

SELL
$86.8 - $118.57 $4.16 Million - $5.68 Million
-47,900 Reduced 64.64%
26,200 $2.82 Million
Q3 2019

Nov 08, 2019

BUY
$83.82 - $101.5 $1.13 Million - $1.37 Million
13,500 Added 22.28%
74,100 $6.68 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $3.32 Million - $4.2 Million
-46,000 Reduced 43.15%
60,600 $5.12 Million
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $2.17 Million - $2.86 Million
31,300 Added 41.57%
106,600 $9.39 Million
Q4 2018

Feb 13, 2019

SELL
$68.32 - $124.36 $3.36 Million - $6.12 Million
-49,200 Reduced 39.52%
75,300 $5.38 Million
Q3 2018

Nov 13, 2018

BUY
$98.88 - $125.85 $12.3 Million - $15.7 Million
124,500 New
124,500 $15.3 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Peak6 Investments LLC Portfolio

Follow Peak6 Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 Investments LLC with notifications on news.